R. De Vivo

Vinorelbine in the treatment of non-small cell lung cancer.

C. Gridelli, R. De Vivo, R. de Vivo, 2002, Current medicinal chemistry.

Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial

S. Pignata, B. Daniele, C. Gallo, 2001, Gut.

Elevation of urinary porphyrin levels following gemcitabine administration.

B. Daniele, R. De Vivo, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of chemotherapy in the management of gastric cancer.

B. Daniele, R. Palaia, V. Parisi, 2000, Journal of clinical gastroenterology.

Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors.

L. Fornaro, C. Vivaldi, G. Aprile, 2018, Cancer treatment reviews.

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study

V. Zagonel, G. Perri, M. Maruzzo, 2022, Targeted Oncology.

Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.

C. Porta, R. Montironi, C. Sternberg, 2015, The Journal of urology.

First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin.

S. Buti, C. Ciccarese, R. Iacovelli, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

S. Pignata, G. Signoriello, G. Scambia, 2006, BMC Cancer.

Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.

S. Pignata, M. Di Maio, A. Ottaiano, 2003, Anticancer research.